MWNA
DICE

Marshall Wace North America’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Marshall Wace North America’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1.41M Buy
+43,062
New +$1.47M 0.01% 822

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Marshall Wace North America's DICE Position: Q3 2021 in Review

Marshall Wace North America opened a new position in DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2021: 43,062 shares worth $1.41M. The stake represents 0.01% of the portfolio and ranks #822 among its holdings.

39 funds tracked by Wall St. Rank hold DICE as of Q3 2021.

  • Marshall Wace North America held 43,062 shares of DICE Therapeutics, Inc. Common Stock worth $1.41M as of Q3 2021.
  • DICE Therapeutics, Inc. Common Stock was a new Marshall Wace North America position in Q3 2021.
  • DICE Therapeutics, Inc. Common Stock made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #822 holding.
  • 39 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.